| Cat.No. | Name | Information |
|---|---|---|
| M10139 | Anakinra | Anakinra (Raleukin) is an antagonist of recombinant, nonglycosylated human IL-1R. |
| M6223 | Tocilizumab | Tocilizumab is a humanized monoclonal antibody that binds to the interleukin-6 receptor. Tocilizumab prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab can be used for the research of rheumatoid arthritis and COVID-19. |
| M6189 | Ossirene | Ossirene (AS101), a potent in vitro and in vivo immunomodulator, is a novel inhibitor of IL-1beta (IL-1β) converting enzyme. Ossirene abolishes phosphorylation of STAT3 by inhibiting IL-10. Ossirene also inhibits Caspase-1. |
| M55699 | Taurohyodeoxycholic acid sodium | Taurohyodeoxycholic acid (THDCA) sodium prevents apoptosis by blocking a calcium-mediated apoptotic pathway as well as caspase-12 activation. Taurohyodeoxycholic acid sodium can also reduce the activity and expression of myeloperoxidase TNF-α and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model. |
| M55336 | IL-4-inhibitor-1 | IL-4-inhibitor-1 is the first IL-4 small-molecule inhibitor, with an EC50 of 1.81 µM. IL-4-inhibitor-1 features a nicotinonitrile scaffold with micromolar affinity and potency for the cytokine and disrupts type II IL-4 signaling in cells. |
| M54800 | 13-Methylberberine chloride | 13-Methylberberine chloride is a berberine analogue, has anti-adipogenic and antitumor activities. 13-Methylberberine chloride increases production of IL-12 and inhibits the expression of iNOS at posttranscriptional level in macrophages activated with LPS. |
| M54551 | Rademikibart | Rademikibart is a human IgG4ҡ monoclonal antibody that targets IL-4 Rα to block inflammatory signaling induced by IL-4 and IL-13, two important cytokines that drive allergic inflammation, and binds to the human IL-4Rα epitope with a KD of 20.7 pM. Rademikibart does not bind to IL-4Rα from other species. Rademikibart does not bind to IL-4Rα of other species.Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMC, and can be used in studies related to moderate-to-severe Th2 inflammatory diseases. |
| M53841 | Ac-YVAD-CHO | Ac-YVAD-CHO (L-709049) is a potent, reversible, specific tetrapeptide interleukin-lβ converting enzyme (ICE) inhibitor with mouse and human Ki values of 3.0 and 0.76 nM. |
| M49644 | Lysophosphatidylcholines | Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). |
| M40875 | Brazikumab | Brazikumab is a human IgG2 monoclonal antibody targeting IL-23 that selectively binds to the p19 subunit of IL-23 and has a KD value of 0.138 nM against human IL-23 for Crohn's disease (CD). |
| M30835 | Lipoxin A4 | Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM. |
| M25309 | Lebrikizumab | Lebrikizumab is a humanized monoclonal antibody to IgG4κ that binds with high affinity and specificity to interleukin 13 (IL-13) and inhibits its function, thereby preventing the formation of the IL-13Rα1/IL-4Rα complex and inhibiting the signaling pathway mediated by this receptor complex.Lebrikizumab has been used in asthma and atopic dermatitis studies. Lebrikizumab may be used in asthma and atopic dermatitis studies. |
| M25286 | Canakinumab | Canakinumab (ACZ885) is a recombinant human anti-IL-1β monoclonal antibody. Canakinumab shows IC50 values of 43.6 and 40.8 pM for human and marmoset IL-1β, respectively. The mode of action of canakinumab is based on the neutralization of IL-1β signaling, resulting in suppression of inflammation related to disorders of autoimmune origin. |
| M25235 | Siltuximab | Siltuximab is an anti-IL-6 (interleukin-6) monoclonal antibody, and shows antitumor activity. Siltuximab can be used in Multicentric Castleman's Disease (MCD) and COVID-19 research. |
| M25229 | Rilonacept | Rilonacept (Arcalyst), a dimeric fusion protein, is a interleukin 1 inhibitor. Rilonacept consists of the ligand-binding domains of the extracellular portions of the IL-1R components linked to the Fc portion of human IgG1. Rilonacept can be used for the research of cryopyrin-associated periodic syndromes. |
| M25215 | Briakinumab | Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. |
| M25180 | Camoteskimab | Camoteskimab (AVTX-007) is a fully human, high-affinity anti-IL-18 monoclonal antibody. Camoteskimab has the potential for the autoinflammatory diseases research, including adult-onset Still’s disease (AOSD). |
| M25102 | Lusvertikimab | Lusvertikimab (OSE-127) is a humanized IL7R monoclonal antibody. Lusvertikimab is not internalized by target cells and prevents IL7R heterodimerization and subsequent downstream signaling. Lusvertikimab has anti-leukemic efficacy and has the potential for B cell precursor acute lymphoblastic leukemia (BCP-ALL) research. |
| M25034 | Urabrelimab | Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction. |
| M25025 | Vixarelimab | Vixarelimab (KPL-716) is a human anti-oncostatin M (OSM) monoclonal antibody that binds to the beta chain of the OSM receptor and inhibits IL-31 and OSM signalling. Vixarelimab can be used in studies of inflammatory skin diseases such as atopic dermatitis and itchy nodular rash. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
